Researchers from the HIV Prevention Trials Network (HPTN) announced today that the HPTN 083 clinical trial showed that a pre-exposure prophylaxis (PrEP) regimen containing long-acting cabotegravir (CAB LA) injected once every eight weeks was superior to daily oral tenofovir/emtricitabine (TDF/FTC) for HIV prevention among cisgender men and transgender women who have sex with men.
The findings, which were reported today at the 23rd International AIDS Conference (AIDS 2020: Virtual), “have have the potential to transform the landscape of HIV prevention for cisgender MSM and transgender women,” said HPTN 083 protocol chair Dr. Raphael J. Landovitz.
The HIV Prevention Trials Network is a worldwide collaborative clinical trials network that develops and tests the safety and efficacy of interventions designed to prevent the transmission of HIV. ICAP’s global director, Wafaa El-Sadr, MD, MPH, MPA, is HPTN co-principal investigator, and ICAP’s Bronx Prevention Center is a participant in the ongoing study.
HPTN 083 is a sister study to another research initiative—the ICAP-led HPTN 084—which is comparing the safety and efficacy of CAB LA to oral TDF/FTC for PrEP among cisgender women in sub-Saharan Africa.
“Offering various HIV prevention options is critically important for control of the global HIV epidemic,” said El-Sadr.